BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced its fourth quarter and full year ended December 31, 2023 financial results and reiterated its 2024 guidance.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year ended December 31, 2023.

Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”), a global leader in supply chain solutions for cell & gene therapies, today announced financial results for the fourth quarter (Q4) and year (FY) ended December 31, 2023.

Precigen, Inc. (Nasdaq: PGEN) today announced that Cantor Fitzgerald will be hosting a virtual fireside chat with Precigen on Monday, March 25, 2024 at 1:00 PM ET to discuss the investigational PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP).

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”) today announced that the Company will participate in the virtual KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024.

Integer Holdings Corporation (NYSE:ITGR) announced today that Joe Dziedzic, President and Chief Executive Officer, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum at 11:15 a.m. ET on Tuesday, March 19, 2024.

Halia Therapeutics today announced that David J. Bearss, Ph.D., President and CEO of Halia Therapeutics, will present at the BIO-Europe Spring 2024 Conference on Tuesday, March 19.

Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”) is excited to announce the highly anticipated release and availability of ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ (“PRIME”) bringing the FDA-approved oral testosterone replacement therapy (TRT) treatment to consumers across the U.S via its proprietary telehealth platform.